CPT code 87182 covers a multiplex immunoassay performed on an organism isolated in culture to detect carbapenemase enzymes, which mediate resistance to carbapenem antibiotics. This laboratory test provides qualitative (positive/negative) screening for multiple carbapenemase targets in a single assay, supporting infection control, antimicrobial stewardship, and therapeutic decision-making. Nationally, identification of carbapenemase-producing organisms is a priority for public health and hospital preparedness because these organisms limit treatment options and are associated with higher morbidity.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines coverage and coding context for these major payers and Medicare, presenting benchmarks for utilization, common billing considerations, and clinical context for laboratory and infection prevention teams.

Readers will learn what CPT code 87182 represents clinically and operationally, typical sites of service and service type, and what to expect in payer coverage landscapes at a high level. The report highlights implications for laboratory workflows, reporting practices, and how this test fits into broader antimicrobial resistance surveillance. Data not provided in the input (such as specific modifier usage, associated taxonomies, ICD-10 pairings, or related codes) are noted as unavailable where applicable.